- Home
- NEWT vs CCCC Comparison
NEWT vs CCCC Comparison
Compare NEWT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWT | CCCC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 185.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEWT | CCCC |
|---|---|---|
| Price | $11.75 | $2.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $14.00 | $12.20 |
| AVG Volume (30 Days) | 167.0K | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.48% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | $5.99 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $9.12 | $1.09 |
| 52 Week High | $14.91 | $3.82 |
Technical Indicators
Market Signals| Indicator | NEWT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 52.31 |
| Support Level | $11.72 | $2.14 |
| Resistance Level | $12.41 | $2.75 |
| Average True Range (ATR) | 0.45 | 0.35 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 15.86 | 26.51 |
Price Performance
Historical ComparisonAbout NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.